Angiogenesis to Headline Anti-Cancer Drug Discovery & Development Conference in Princeton, NJ, June 11 & 12.

Apr 04, 2001, 01:00 ET from Strategic Research Institute

    PRINCETON, N.J., April 4 /PRNewswire/ -- Late-breaking advances in
 anti-cancer research in angiogenesis, therapeutic antibodies, genomics, and
 new molecular targets at the pre-clinical and clinical stages will be the
 focus of the "2nd International Anti-Cancer Drug Discovery & Development
 Summit" taking place in Princeton, NJ on June 11-12, 2001, announces Strategic
 Research Institute.
     Presentations on angiogenic advances will be given by Merck, EntreMed,
 ILEX Oncology, and Georgetown University, all of whom are researching the
 effectiveness of angiogenesis against a variety of human cancers, a hypothesis
 that is currently being tested in the clinic.
     The meeting, divided into five discrete sections, 1) new molecular
 targets, 2) therapeutic antibodies, 3) applied genomics in oncology, 4)
 angiogenic advances, and 5) novel therapeutics, will feature prominent
 pharmaceutical, biotechnology, and academic scientists revealing their newest
 findings.
     Also presenting papers on behalf of the industry will be, Novartis, Amgen,
 Hoffmann-La Roche, Bristol-Myers Squibb, Eli Lilly, Schering-Plough, Wyeth
 Ayerst, Millennium Pharmaceuticals, Celera Genomics, Cytokinetics, Eos
 Biotechnology, ImClone Systems, Medarex, Biomira, and Ceretek, while Columbia
 University will represent the academic community.
 
     Other highlights of the program include:
 
     -- Development of a Novel Epothilone for the Treatment of Cancer by
        BRISTOL-MYERS SQUIBB
 
     -- CD22-Directed Immunotherapy of Non-Hodgkin Lyphoma by AMGEN
 
     -- Application of Genomics and Proteomics to the Development of
        Diagnostics and Therapeutics for Cancer by CELERA GENOMICS
 
     To receive the full agenda and/or register for the conference, please
 contact Jon Liong of Strategic Research Institute at jliong@srinstitute.com or
 212-967-0095, ext. 243 (please include name, corporate affiliation, mailing
 address, and fax number).
     To register as an exhibitor or to sponsor a function, please contact Mark
 Alexay at malexay@srinstitute.com.
 
 

SOURCE Strategic Research Institute
    PRINCETON, N.J., April 4 /PRNewswire/ -- Late-breaking advances in
 anti-cancer research in angiogenesis, therapeutic antibodies, genomics, and
 new molecular targets at the pre-clinical and clinical stages will be the
 focus of the "2nd International Anti-Cancer Drug Discovery & Development
 Summit" taking place in Princeton, NJ on June 11-12, 2001, announces Strategic
 Research Institute.
     Presentations on angiogenic advances will be given by Merck, EntreMed,
 ILEX Oncology, and Georgetown University, all of whom are researching the
 effectiveness of angiogenesis against a variety of human cancers, a hypothesis
 that is currently being tested in the clinic.
     The meeting, divided into five discrete sections, 1) new molecular
 targets, 2) therapeutic antibodies, 3) applied genomics in oncology, 4)
 angiogenic advances, and 5) novel therapeutics, will feature prominent
 pharmaceutical, biotechnology, and academic scientists revealing their newest
 findings.
     Also presenting papers on behalf of the industry will be, Novartis, Amgen,
 Hoffmann-La Roche, Bristol-Myers Squibb, Eli Lilly, Schering-Plough, Wyeth
 Ayerst, Millennium Pharmaceuticals, Celera Genomics, Cytokinetics, Eos
 Biotechnology, ImClone Systems, Medarex, Biomira, and Ceretek, while Columbia
 University will represent the academic community.
 
     Other highlights of the program include:
 
     -- Development of a Novel Epothilone for the Treatment of Cancer by
        BRISTOL-MYERS SQUIBB
 
     -- CD22-Directed Immunotherapy of Non-Hodgkin Lyphoma by AMGEN
 
     -- Application of Genomics and Proteomics to the Development of
        Diagnostics and Therapeutics for Cancer by CELERA GENOMICS
 
     To receive the full agenda and/or register for the conference, please
 contact Jon Liong of Strategic Research Institute at jliong@srinstitute.com or
 212-967-0095, ext. 243 (please include name, corporate affiliation, mailing
 address, and fax number).
     To register as an exhibitor or to sponsor a function, please contact Mark
 Alexay at malexay@srinstitute.com.
 
 SOURCE  Strategic Research Institute